Stock BIIB BIOGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Biogen Inc.

Equities

BIIB

US09062X1037

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-03 pm EDT 		5-day change 1st Jan Change
217.5 USD +1.87% Intraday chart for Biogen Inc. +4.12% -15.94%
May. 03 HSBC Adjusts Price Target on Biogen to $342 From $339, Maintains Buy Rating MT
Apr. 30 Wall Street: buoyed by Tesla, confident ahead of FOMC meeting CF

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Biogen Reports Progress on Corporate Responsibility Priorities
AQ
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
GL
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
PR
Biogen : Update on European Medicines Agency Review of Lecanemab Marketing Authorization Application
PU
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
BU
InvestorBrandMedia: Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth
AQ
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
BU
Biogen : to Participate in the Stifel 2024 Virtual CNS Days
PU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIB
PR
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
GL
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
AQ
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
GL
BYOOVIZ Is Confusing With BEOVU: Federal Court Finds Violation Of Novartis' Trademark Rights
AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIB
PR
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
BU
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
GL
Law Offices of Howard G. Smith Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
BU
The Law Offices of Frank R. Cruz Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
BU
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
GL
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BIIB Stock
  4. News Biogen Inc.
  5. Press Releases